Core Viewpoint - Hutchison China MediTech Limited (Chi-Med) announced that its drugs ELUNATE, ORPATHYS, and SULANDA will continue to be included in the updated National Medical Insurance Drug List effective from January 1, 2026, following a renewal agreement with the National Healthcare Security Administration of China. Additionally, TAZVERIK has been included in the inaugural National Commercial Health Insurance Innovative Drug List [1]. Group 1 - Chi-Med's drugs ELUNATE, ORPATHYS, and SULANDA will remain in the National Medical Insurance Drug List starting January 1, 2026 [1]. - The renewal agreement with the National Healthcare Security Administration ensures continued access to these medications for patients [1]. - TAZVERIK has been added to the first version of the National Commercial Health Insurance Innovative Drug List [1].
和黄医药：达唯珂 (TAZVERIK )获纳入首版国家商业健康保险创新药品目录